Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
55 hedge funds and large institutions have $1.54B invested in Rubius Therapeutics, Inc in 2018 Q3 according to their latest regulatory filings, with 55 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$876M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$142M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$89.4M |
| 4 |
AG
Artal Group
Luxembourg
|
+$66.5M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$66.1M |
Top Sellers
RUBY Hedge Fund Activity: Q3 2018 in Review
55 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q3 2018, worth a combined $1.54B.
Buyers outnumbered sellers: 55 funds opened new RUBY positions and 0 closed out — a net gain of 55 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Flagship Pioneering, opening a new position worth an estimated $876M.
- 55 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q3 2018, up from 0 in Q2 2018.
- Funds reported $1.54B of Rubius Therapeutics, Inc stock for Q3 2018.
- 55 funds opened new Rubius Therapeutics, Inc positions in Q3 2018 and 0 closed out, a net change of +55 holders.
- The largest Rubius Therapeutics, Inc buyer in Q3 2018 was Flagship Pioneering, an estimated $876M added.
Based on aggregated 13F filings for Q3 2018.